Latest News Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC “Blockbuster” Therapy Dec 29 2025 Latest News Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference Dec 23 2025 Latest News Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors-BeOne Dec 11 2025 Media Coverage Senhwa Biosciences Partners with BeOne for Advanced Cancer Treatment Dec 11 2025 Media Coverage Google's AI model identified Silmitasertib (CX-4945) as a potential key to boosting tumor antigen presentation by turning cold tumors to hot ones, a new potential cancer therapy pathway. Oct 16 2025 Media Coverage Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today Jun 25 2025 Publications Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy Jul 11 2025 Publications Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL Mar 27 2025 Publications Fibroblast growth receptor 1 is regulated by G-quadruplex in metastatic breast cancer Aug 09 2024